Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Sees Significant Increase in Short Interest

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 93,732 shares, an increase of 264.3% from the September 15th total of 25,732 shares. Based on an average trading volume of 1,091 shares, the days-to-cover ratio is currently 85.9 days.

Analyst Ratings Changes

Separately, Danske assumed coverage on shares of Hansa Biopharma AB (publ) in a report on Tuesday, June 16th. They issued a “buy” rating on the stock. Four equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Hansa Biopharma AB (publ) has a consensus rating of “Buy”.

Hansa Biopharma AB (publ) Price Performance

Shares of OTCMKTS:HNSBF opened at $3.29 on Tuesday. The company’s 50-day moving average price is $3.62 and its two-hundred day moving average price is $3.17. Hansa Biopharma AB has a one year low of $2.90 and a one year high of $3.70.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ) is a Swedish biotechnology company focused on developing and commercializing treatments for rare immunological conditions. The company’s technology is designed to selectively modulate the immune system, with the goal of enabling medical procedures and addressing diseases in which pathogenic antibodies play a significant role.

Its leading product is Idefirix (imlifidase), an enzyme therapy that rapidly cleaves immunoglobulin G antibodies. Idefirix is approved in the European Union for desensitization treatment of highly sensitized adult kidney transplant patients who are unlikely to receive a transplant under the available kidney allocation system.